|Bid||0.00 x 800|
|Ask||0.00 x 900|
|Day's range||5.55 - 5.68|
|52-week range||3.02 - 11.95|
|Beta (5Y monthly)||-0.14|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||9.90|
MARSEILLE, France, October 15, 2021--Regulatory News: Pursuant to the article L. 233-8 II of the French "Code de Commerce" and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") General Regulation, Innate Pharma SA (Euronext Paris:– IPH; Nasdaq: IPHA) ("Innate" or the "Company") releases its total number of shares outstanding as well as its voting rights as at October 1, 2021:
Shares of Innate Pharma (NASDAQ: IPHA), a clinical-stage biotechnology company, are rocketing higher in response to successful clinical-trial data for an experimental cancer drug called monalizumab. Monalizumab is currently in a phase 2 trial called Coast, in combination with Imfinzi from AstraZeneca (NASDAQ: AZN). Imfinzi is approved to treat advanced-stage non-small cell lung cancer (NSCLC) patients with tumors that haven't grown since beginning standard first-line treatment.
9, 2021 /CNW/ - QUESTEX GOLD & COPPER LTD. (TSX-V: QEX) ("QuestEx" or the "Company") is pleased to announce the results from a 2020 exploration program on its 100% owned 91 square-kilometre ("km") Sofia property in British Columbia's prolific Toodoggone Mining District (Figure 1).